H4D facilitates access to healthcare by allowing patients to consult a doctor remotely in the Consult Station®, the first connected local telemedicine booth. This medical device allows quality healthcare to be delivered for primary care, occupational health, and general health promotion.
Featuring articles on lung-cancer screening in the NELSON trial, ribociclib and fulvestrant in metastatic breast cancer, vitamin D in pregnancy and asthma, treatment thresholds for neonatal hypoglycemia, and CAR-NK cells in anti-CD19 lymphoid tumors; a review article on placebo and nocebo effects; a Clinical Problem-Solving describing a rapid change in pressure; and Perspective articles on altruism in Extremis, on abuses of FDA regulatory procedures, and on joining forces against delirium.
A new Artificial Intelligence (AI) model predicts breast cancer in mammograms more accurately than radiologists, reducing false positives and false negatives, reports a large international study from Google, Northwestern Medicine and two screening centers in the United Kingdom (U.K.).
Telemedicine extends care accessibility to people with epilepsy, who may be unable to drive to appointments, as well as people with mobility issues stemming from neurologic disorders such as multiple sclerosis. Virtual care also helps address geographic barriers by allowing patients in rural areas to see a neurologist through telemedicine technology instead of having to travel hours for in-person care, said lead author Jaime Hatcher-Martin, MD, PhD, a member of AAN, according to the news release.
The studies’ analysis found that patients and their caregivers were equally satisfied with virtual physician visits and in-person appointments. Some studies showed that the use of telemedicine is as effective as in-person care to make accurate diagnoses. However, the researchers noted that there have been few randomized, controlled studies on telemedicine for neurology apart from stroke care.
“Such wearable sweat sensors have the potential to rapidly, continuously, and noninvasively capture changes in health at molecular levels,” Gao says. “They could enable personalized monitoring, early diagnosis, and timely intervention.”
The development of such sensors would allow doctors to continuously monitor the condition of patients with illnesses like cardiovascular disease, diabetes, or kidney disease, all of which result in abnormal levels of nutrients or metabolites in the bloodstream. Patients would benefit from having their physician better informed of their condition, while also avoiding invasive and painful encounters with hypodermic needles.
Gao’s work is focused on developing devices based on microfluidics, a name for technologies that manipulate tiny amounts of liquids, usually through channels less than a quarter of a millimeter in width. Microfluidics are ideal for an application of this sort because they minimize the influence of sweat evaporation and skin contamination on the sensing accuracy. As freshly supplied sweat flows through the microchannels, the device can make more accurate measurements of sweat and can capture temporal changes in concentrations.
From a Radiological Society of North America release:
The TACT Pivotal study of MRI-guided TULSA for whole-gland ablation in men with localized prostate cancer met its primary PSA endpoint in 96% of patients, with low rates of severe toxicity and residual GG2 disease. MRI at 12mo detected residual disease with NPV of 93%.
The new technique is called MRI-guided transurethral ultrasound ablation (TULSA) and has been under development for a number of years. The minimally invasive technology involves a rod that enters the prostate gland via the urethra and emits highly controlled sound waves in order to heat and destroy diseased tissue, while leaving healthy tissue unharmed.
Philips Lumify ultrasound technology is an important component of the mobile ECMO unit. Members of the ECMO team use Lumify for real-time visual guidance when inserting tubes in veins and arteries in a process called ECMO cannulation.
“Lumify has excellent image quality and is easy to use – it was instrumental in our first pre-hospital ECMO cannulation,” said Dr. Darren Braude.
Physicians from the University of New Mexico (UNM) and local emergency responders recently treated a cardiac arrest patient with the first ever out-of-hospital portable life-support system available in the United States.
The machine performs a function called extracorporeal membrane oxygenation, or ECMO. ECMO machines mimic a functioning heart and lungs, circulating oxygenated blood for patients who have suffered a cardiac arrest.
This proposed agency could work like a seal of approval, like the Energy Star program run by the Environmental Protection Agency, for new software, apps, and vendors that will be handling sensitive health information. Just like dishwashers evaluated by Consumer Reports, apps that handle personal health information should have a similar unbiased review process.
The US health care system is finally at a tipping point of much needed and overdue modernization. While it promises a brave new world of streamlined and improved health care, we are facing nothing short of a revolutionary transformation that is based on a tsunami of readily accessible health information and digital tools.
Currently, there is no federal agency, public-private collaboration, or private industry mechanism that is prepared to handle the ensuing activity in its entirety. We need to get a handle on how best to protect our private health care data while also making sure that information is allowed to flow as freely as necessary to improve our delivery system and population’s health. We need a dedicated team of experts who speak the language of both information technology and public policy. We need a new federal agency that has jurisdiction and dedicated staff to oversee health information and the technology that will simplify and operationalize the information.
Our 3D deep-learning system performed well in both primary and external validations, suggesting that it could potentially be used for automated detection of glaucomatous optic neuropathy based on SDOCT volumes. Screening with the deep-learning system is much faster than conventional glaucoma screening methods (ie, by experienced specialists), can be done automatically, and does not require a large number of trained personnel on site. Further prospective studies are warranted to estimate the incremental cost-effectiveness of incorporating this artificial intelligence-based model for screening for glaucoma, both in the general population and among at-risk people.
Now, researchers have developed a fast-acting skin patch that efficiently delivers medication to attack melanoma cells. The device, tested in mice and human skin samples, is an advance toward developing a vaccine to treat melanoma and has widespread applications for other vaccines.
Nearly 100,000 new cases of melanoma are diagnosed annually, and 20 Americans die every day from it. Now, researchers have developed a skin patch that efficiently delivers medication within one minute to attack melanoma cells. The device, tested in mice and human skin samples, also could be adapted to deliver other vaccines.
“Our patch has a unique chemical coating and mode of action that allows it to be applied and removed from the skin in just a minute while still delivering a therapeutic dose of drugs,” says Yanpu He, a graduate student who helped develop the device. “Our patches elicit a robust antibody response in living mice and show promise in eliciting a strong immune response in human skin.”